Armas, Micro Labs USA partner to launch generic injectables
Armas Pharmaceuticals and Micro Labs USA have formed a strategic collaboration to bring select multisource injectable products to the U.S. market.
The first product launched last month is diphenhydramine injection 50mg/1mL. Diphenhydramine has been seen on the Food and Drug Administration’s drug shortage list since September 2018. Additional product launches are set for the second quarter of 2019. The market size of these products total $100 million annually, according to IQVIA data.
“Armas Pharmaceuticals is excited to partner with Micro Labs as we look to expand our product line across multiple therapeutic classes,” said John Niemi, Armas president and CEO. “Our first launch with Micro Labs, diphenhydramine injection 50mg/1mL, is a medicinal drug used widely in the healthcare space. It is our aim to make this product available at affordable pricing to patients in need of the same. This medication reinforces our ultimate goal to bring high quality, affordable drugs that are needed in the U.S. market.”
“Micro and Armas have been working together on various ideas and projects. We are proud to be associated with Armas and we truly value the rich experience and understanding of the U.S. healthcare sector they bring to the partnership,” Ashok Jain, Micro Labs USA’s director said.
No comments found